RecruitingPhase 4NCT06431477

Efficacy and Safety of Telmisartan Compared With Losartan

A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared With Losartan in Patients With Diabetic Nephropathy and Hypertension


Sponsor

Chong Kun Dang Pharmaceutical

Enrollment

98 participants

Start Date

Apr 19, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension


Eligibility

Min Age: 19 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two blood pressure medications — telmisartan and losartan — to see which works better for people with type 2 diabetes who also have high blood pressure or kidney-related complications. **You may be eligible if...** - You are between 19 and 74 years old (male or female) - You have been diagnosed with type 2 diabetes and are currently taking medication for it - You are willing to participate and have signed the consent form **You may NOT be eligible if...** - You have type 1 diabetes - You have a condition called primary hyperaldosteronism (an adrenal gland disorder) - You have a history of drug or alcohol abuse within the past year - You are pregnant, breastfeeding, or unwilling to use contraception during the trial - You have participated in another clinical trial drug study within the past 28 days - Your doctor does not think it is safe for you to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGtelmisartan

QD, PO

DRUGLosartan

QD, PO


Locations(1)

Severance Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06431477


Related Trials